MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Exploring minzasolmin effect on digital measures captured by the Verily Study Watch in a subset of the ORCHESTRA trial participants

    B. Bloem, V. Hinson, E. Goikoetxea, L. Gaetano, K. Ray, F. Ambrosetti, KC. Ho, M. Key Prato, A. Pethe, V. Ticcinelli, J. Trzebinski, S. Warma, A. Khanna, Z. Ali (Nijmegen, Netherlands)

    Objective: To investigate the progression over time and the effect of minzasolmin on digital outcomes collected in ORCHESTRA (NCT04658186). Background: Minzasolmin is an oral small…
  • 2025 International Congress

    Long-Term Effect of Opicapone in Parkinson’s Patients Without Motor Complications: 1.5-year EPSILON Study Findings

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, H. Brigas, J. Moreira, JF. Rocha, M. Fonseca, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: We report motor function, motor complication and tolerability findings of the EPSILON study up to 1.5 years. Background: The 24-week, double-blind, placebo-controlled Phase III…
  • 2025 International Congress

    NIH funds Gut-Brain Parkinson’s Disease Consortium

    C. Goetz, L. Becker, A. Bharucha, E. Chang, A. Keshavarzian, B. Kuo, K. Newby, K. Poston, L. Sanders, R. Savica, A. Sharma, A. Videnovic, L. Wruck, T. Xie (Chicago, USA)

    Objective: Describe the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) multicenter (UO1) Consortium on PD Gut-Brain Communication. Background: A 2024 Notice of Funding…
  • 2025 International Congress

    Dual-task gait digital assessment unmask the association between dopaminergic deficits and gait parameters in early and prodromal Parkinson’s Disease

    A. Pilotto, C. Zatti, A. Rizzardi, A. Galli, C. Hansen, J. Geritz, R. Rominjnders, E. Schaeffer, M. Catania, A. Lupini, T. Comunale, E. Premi, M. Pasolini, S. Lucchini, F. Brertagna, B. Paghera, S. Caminiti, D. Perani, D. Berg, W. Maetzler, A. Padovani (Brescia, Italy)

    Objective: to explore the relationship between dopaminergic deficits and digital gait parameters alterations in de novo PD and iRBD Background: gait alterations are common features…
  • 2025 International Congress

    Antiparkinson Medication Reduces the Probability of the Multiple Step Saccade Pattern During a Memory-Guided Saccade Task

    M. Munoz, J. Reilly, E. Zou, Y. Rivera, G. Pal, L. Verhagen Metman, L. Goelz, D. Corcos, F. David (Chicago, USA)

    Objective: We wanted to determine how the multiple step saccade pattern responds to antiparkinson medication, as it has been proposed to use this pattern as…
  • 2025 International Congress

    Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States

    N. Crouse, C. Happel, M. Grall (Rockville, USA)

    Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…
  • 2025 International Congress

    Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study

    K. Kakuda, Y. Kimura, K. Ikenaka, H. Mochizuki (Suita, Japan)

    Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…
  • 2025 International Congress

    Zonisamide for Motor Symptoms and OFF-Time Reduction in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the efficacy and safety of zonisamide as an adjunct therapy for improving motor function and reducing OFF-time in patients with Parkinson’s disease…
  • 2025 International Congress

    Unraveling the Intertwined Relationship of DBS, Parkinson’s Disease Subtype and LEDD: A Retrospective Study

    T. Mehta, V. Lavu, C. Hess, A. Ramirez-Zamora, M. Okun, J. Wong (Gainesville, USA)

    Objective: To assess the impact of deep brain stimulation (DBS) target and Parkinson’s disease (PD) motor subtype on the total levodopa equivalent daily dose (LEDD)…
  • 2025 International Congress

    Carvacrol modulates rotenone-induced Nigrostriatal Neuronal Death and Angiogenesis via targeting AMPK/FOXO3 transcription factor O3 Signaling cascade

    D. Singh (Allahabad, India)

    Objective: With an eye toward its effects on striatal angiogenesis and the AMPK/ FOXO3 transcription factor O3 pathway, this work attempts to investigate the neuroprotective…
  • « Previous Page
  • 1
  • …
  • 106
  • 107
  • 108
  • 109
  • 110
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley